Telemedicine’s future: A return to the prepandemic status quo?
“There is a lot of debate about the final shape and form of what telemedicine should look like,” says Chad Ellimoottil, MD, MS, in this video.
In this video, Chad Ellimoottil, MD, MS, shares his thoughts on reimbursement for telemedicine as more of the population is vaccinated against COVID-19. Ellimoottil is Assistant Professor of Urology and Director of the University of Michigan’s Telehealth Research Incubator.
Dr. Lacouture on managing dermatological adverse events with apalutamide in prostate cancer
February 7th 2022To investigate the severity and prevalence of dermatologic adverse events associated with apalutamide, Mario E. Lacouture, MD, and investigators conducted a study that will help to manage and counsel patients with prostate cancer in the future, especially with the expanded approval of apalutamide in this space.
How appropriate use criteria for PSMA-PET imaging optimize patient care
February 2nd 2022In a recent interview, Hossein Jadvar, MD, PhD, discussed what the appropriate use criteria consist of for prostate-specific membrane antigen (PSMA)-PET imaging, and why these criteria are vital in ensuring the individualized care of patients.
Dr. Padmanabhan discusses impact of COVID-19
June 11th 2020Urology Times® Editorial Council Member Priya Padmanabhan, MD, MPH, professor of urology at Oakland University William Beaumont School of Medicine, Royal Oak, Michigan, discusses how she has been affected by the coronavirus disease 2019 (COVID-19) pandemic.
